VanEck Pharmaceutical ETF
PPH
50 hedge funds and large institutions have $93M invested in VanEck Pharmaceutical ETF in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
4% more funds holding
Funds holding: 48 → 50 (+2)
7% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 15
22.17% less ownership
Funds ownership: 55.6% → 33.43% (-22%)
32% less capital invested
Capital invested by funds: $136M → $93M (-$43.1M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $339K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
+$7M |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.72M |
| 3 |
Jane Street
New York
|
+$1.26M |
| 4 |
Morgan Stanley
New York
|
+$1.23M |
| 5 |
Citigroup
New York
|
+$1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$64.8M |
| 2 |
Goldman Sachs
New York
|
-$5.78M |
| 3 |
SG Americas Securities
New York
|
-$5.73M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.37M |
| 5 |
CC
Colrain Capital
Boston,
Massachusetts
|
-$578K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCA
51
Conservest Capital Advisors
Wynnewood,
Pennsylvania
| – | -$289K | -5,000 | Closed |
|
52
Ameriprise
Minneapolis,
Minnesota
| – | -$264K | -4,567 | Closed |
|
|
MA
53
MUFG Americas
New York
| – | -$61K | -1,050 | Closed |
|
|
EDRH
54
Edmond de Rothschild Holding
Chambesy,
Switzerland
| – | -$12K | -200 | Closed |
|
PPH Hedge Fund Activity: Q4 2017 in Review
50 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2017, worth a combined $93M — down 32% from $136M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PPH positions and 5 closed out — a net gain of 2 holders — while 14 added to existing stakes and 15 trimmed.
The largest buyer was Brinker Capital Investments, adding an estimated $7M. The largest seller was Bank of America, cutting an estimated $64.8M.
- 50 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2017, up from 48 in Q3 2017.
- Funds reported $93M of VanEck Pharmaceutical ETF stock for Q4 2017, down 32% quarter-over-quarter.
- 7 funds opened new VanEck Pharmaceutical ETF positions in Q4 2017 and 5 closed out, a net change of +2 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q4 2017 was Brinker Capital Investments, an estimated $7M added.
- The largest VanEck Pharmaceutical ETF seller in Q4 2017 was Bank of America, an estimated $64.8M sold.
Based on aggregated 13F filings for Q4 2017.